[REVISION HISTORY]
Mexico pharmaceutical and healthcare market developments
2 recorded revisions of this situation.
What changed
2026-10-20 23:54 UTC → 2026-10-21 16:03 UTC ·
added
removed
The Mexican pharmaceutical and healthcare sectors are navigating a complex landscape of significant financial liabilities and market expansion. The federal government has officially recognized a debt of 110.8 billion pesos owed to the pharmaceutical industry, an amount representing roughly 63 percent of the projected 2026 budget for IMSS-Bienestar. This debt includes outstanding invoices from procurement processes dating back to 2023. Industry groups, including Amelaf and Concamin, have called for immediate liquidation of these debts, warning that delayed payments could lead to shortages of essential supplies in hospitals and clinics. Furthermore, Mexican business leaders have raised concerns regarding competition in public tenders, arguing that procurement from suppliers in countries such as India and China creates an uneven playing field due to potential state subsidies, which they claim distorts competition and threatens local production. Despite these debt challenges, the broader market shows strong growth potential. Estimates suggest the Mexican pharmaceutical market is valued at approximately USD 20 billion to USD 22.6 billion in 2026, with projections indicating it could double by 2033. This growth is being driven by rising expenditure, innovation, and an aging demographic. In a recent development, President Claudia Sheinbaum announced that the federal government has achieved savings of approximately 70 billion pesos in the procurement of medicines and medical supplies compared to 2024 costs. These savings were attributed to a consolidated purchasing scheme involving costs through direct contracting with manufacturers, contracting, reverse auctions, and contract reviews. To enhance transparency, officials plan to automate warehouses, implement traceability systems, and enable digital platforms for public contract monitoring. Eduardo Clark García Dobarganes, Undersecretary of Sectoral Integration and Coordination of Medical Care Services, stated that the strategy aims to “eliminate intermediaries and promote competition.” The government is currently preparing to acquire approximately 6 billion units of medicines and medical supplies for the 2027-2028 period, including oncology treatments. Officials also noted they are investigating previous high-cost contracts, citing one instance including a 1.7 billion peso contract in the State of Mexico where contract modifications resulted suspected of overcosts in paying 32 percent less while moving 40 percent more units. distribution and pharmacy operations.
Versions
- 2026-10-21 16:03 UTC Mexico pharmaceutical and healthcare market developments
- 2026-10-20 23:54 UTC Mexico pharmaceutical and healthcare market developments
- 2026-10-02 13:21 UTC Mexico pharmaceutical and healthcare market developments
Select a version to see what changed compared to the one before it.